Trial Profile
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Encequidar+paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 06 Sep 2021 Status changed from recruiting to completed.
- 24 Mar 2020 Planned End Date changed from 1 Mar 2020 to 1 Nov 2020.
- 24 Mar 2020 Planned primary completion date changed from 1 Sep 2019 to 1 Jun 2020.